Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Effects of Anesthesia on Maternal and Fetal Oxidative Stress During Cesarean Delivery

5 novembre 2026 aggiornato da: University of Banja Luka

The Impact of Target-Controlled Infusion of Propofol on Fetal Oxidative Stress During Anesthesia for Cesarean Section

Oxidative stress occurs when the production of reactive molecules exceeds the body's antioxidant defenses. Pregnancy is associated with physiological changes that may increase oxidative stress in both the mother and fetus. The type of anesthesia used during cesarean delivery may influence this process.

This study aimed to investigate whether general anesthesia using target-controlled infusion (TCI) of propofol affects maternal and fetal oxidative stress compared with spinal anesthesia and general anesthesia using thiopental and sevoflurane.

A total of 90 healthy pregnant women undergoing elective cesarean delivery were included in this prospective study. Participants were divided into three groups of 30: spinal anesthesia, propofol-based general anesthesia, and thiopental-sevoflurane general anesthesia.

Maternal venous blood, umbilical venous blood, and placental tissue samples were collected to assess biochemical markers of oxidative stress and antioxidant defense. Clinical and anesthesia-related data were also recorded.

The study was designed to compare oxidative stress markers across the three anesthesia techniques and evaluate the potential antioxidant effects of propofol on the mother and fetus.

Panoramica dello studio

Descrizione dettagliata

This prospective, open-label clinical study was conducted at the University Clinical Centre of the Republic of Srpska in Banja Luka, Bosnia and Herzegovina, to investigate the effects of different anesthetic techniques on maternal and fetal oxidative stress during elective cesarean delivery.

The study included 90 pregnant women with uncomplicated pregnancies undergoing elective cesarean delivery. Participants were allocated to three groups of 30 according to the anesthetic technique: spinal anesthesia (Group S), general anesthesia with target-controlled infusion of propofol (Group P), and general anesthesia with thiopental induction followed by sevoflurane maintenance (Group TS).

Maternal venous blood, umbilical venous blood, and placental tissue samples were collected to assess oxidative stress and antioxidant defense mechanisms. The biochemical analyses included markers of lipid peroxidation, reactive oxygen species, and antioxidant activity, including thiobarbituric acid-reactive substances (TBARS), nitrites, hydrogen peroxide, superoxide anion, superoxide dismutase (SOD), reduced glutathione (GSH), and catalase (CAT).

Maternal hemodynamic parameters, anesthetic drug administration, neonatal clinical outcomes, and postoperative maternal outcomes were also evaluated.

The study aimed to compare oxidative stress responses across the three anesthetic techniques and investigate whether propofol-based total intravenous anesthesia provides potential antioxidant benefits in the maternal-placental-fetal system.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

90

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Republika Srpska
      • Banja Luka, Republika Srpska, Bosnia Erzegovina, 78000
        • University Clinical Centre of the Republic of Srpska

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Uncomplicated singleton pregnancy.
  • Estimated fetal weight greater than 2500 g.
  • Scheduled elective cesarean delivery.
  • Written informed consent to participate in the study.

Exclusion Criteria:

  • Emergency cesarean delivery.
  • Thrombophilia.
  • Hypertensive disorders of pregnancy.
  • Diabetes mellitus.
  • Maternal smoking.
  • Intrauterine fetal growth restriction (IUGR).
  • Fetal malformations.
  • Intrauterine fetal death.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Scienza basilare
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Arm 1 - Spinal anesthesia

Thirty women undergoing elective cesarean section under spinal anesthesia.

Spinal anesthesia administered for elective cesarean section as part of routine clinical care.

Sperimentale: Arm 2 - Propofol TCI

Thirty women undergoing elective cesarean section under general anesthesia using target-controlled infusion of propofol.

General anesthesia using target-controlled infusion of propofol for elective cesarean section.

Comparatore attivo: Arm 3 - Thiopental-Sevoflurane

Thirty women undergoing elective cesarean section under general anesthesia with thiopental induction and sevoflurane maintenance.

Thiopental was administered intravenously for induction of general anesthesia in women undergoing elective cesarean section. Anesthesia was subsequently maintained with sevoflurane.

Sevoflurane was administered by inhalation for maintenance of general anesthesia during elective cesarean section, following intravenous induction with thiopental.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Maternal Plasma TBARS Concentration
Lasso di tempo: Before anesthesia, during cesarean delivery, and 2 hours postoperatively.

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in maternal plasma. Concentrations were compared across the three anesthesia groups and assessed at three perioperative time points. Values are expressed in mmol/L.

Before anesthesia, during cesarean delivery, and 2 hours postoperatively.
Umbilical Cord Venous Plasma TBARS Concentration
Lasso di tempo: At delivery (umbilical cord venous blood sampling).

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in mmol/L.

At delivery (umbilical cord venous blood sampling).
Placental Tissue TBARS Concentration
Lasso di tempo: At delivery, immediately following placental removal.

Thiobarbituric acid-reactive substances (TBARS), an indicator of lipid peroxidation, measured in placental tissue homogenates. Concentrations were compared across the three anesthesia groups. Values are expressed in µmol/g of tissue.

At delivery, immediately following placental removal.
Maternal Plasma Hydrogen Peroxide (H2O2) Concentration
Lasso di tempo: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Hydrogen peroxide (H2O2), a marker of oxidative stress, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Hydrogen Peroxide (H2O2) Concentration
Lasso di tempo: At delivery (umbilical cord venous blood sampling).

Hydrogen peroxide (H2O2), a marker of oxidative stress, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Plasma Superoxide Anion (O2-) Concentration
Lasso di tempo: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Superoxide anion (O2-), a reactive oxygen species and marker of oxidative stress, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Superoxide Anion (O2-) Concentration
Lasso di tempo: At delivery (umbilical cord venous blood sampling).

Superoxide anion (O2-), a reactive oxygen species and marker of oxidative stress, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Plasma Nitrite (NO2-) Concentration
Lasso di tempo: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Nitrite (NO2-), an indicator of nitric oxide metabolism, measured in maternal plasma. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Plasma Nitrite (NO2-) Concentration
Lasso di tempo: At delivery (umbilical cord venous blood sampling).

Nitrite (NO2-), an indicator of nitric oxide metabolism, measured in umbilical cord venous plasma. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL.

At delivery (umbilical cord venous blood sampling).
Maternal Erythrocyte Superoxide Dismutase (SOD) Activity
Lasso di tempo: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in maternal erythrocyte lysates. Activity was compared across the three anesthesia groups at three perioperative time points. Values are expressed in U/g Hgb × 10³.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Superoxide Dismutase (SOD) Activity
Lasso di tempo: At delivery (umbilical cord venous blood sampling).

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in erythrocyte lysates from umbilical cord venous blood. Activity was compared across the three anesthesia groups. Values are expressed in U/g Hgb × 10³.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Superoxide Dismutase (SOD) Activity
Lasso di tempo: At delivery, following placental removal.

Superoxide dismutase (SOD) activity, an indicator of enzymatic antioxidant defense, measured in placental tissue homogenates. Activity was compared across the three anesthesia groups. Values are expressed in U/g of tissue.

At delivery, following placental removal.
Maternal Erythrocyte Reduced Glutathione (GSH) Concentration
Lasso di tempo: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in maternal erythrocyte lysates. Concentrations were compared across the three anesthesia groups at three perioperative time points. Values are expressed in nmol/mL RBC.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Reduced Glutathione (GSH) Concentration
Lasso di tempo: At delivery (umbilical cord venous blood sampling).

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in erythrocyte lysates from umbilical cord venous blood. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/mL RBC.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Reduced Glutathione (GSH) Concentration
Lasso di tempo: At delivery, following placental removal.

Reduced glutathione (GSH), a non-enzymatic antioxidant involved in cellular defense against oxidative stress, measured in placental tissue homogenates. Concentrations were compared across the three anesthesia groups. Values are expressed in nmol/g of tissue.

At delivery, following placental removal.
Maternal Erythrocyte Catalase (CAT) Activity
Lasso di tempo: Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in maternal erythrocyte lysates. Activity was compared across the three anesthesia groups at three perioperative time points. Values are expressed in U/g Hgb × 10³.

Before anesthesia, after delivery and placental removal, and 2 hours postoperatively.
Umbilical Cord Venous Erythrocyte Catalase (CAT) Activity
Lasso di tempo: At delivery (umbilical cord venous blood sampling).

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in erythrocyte lysates from umbilical cord venous blood. Activity was compared across the three anesthesia groups. Values are expressed in U/g Hgb × 10³.

At delivery (umbilical cord venous blood sampling).
Placental Tissue Catalase (CAT) Activity
Lasso di tempo: At delivery, following placental removal.

Catalase (CAT) activity, an indicator of enzymatic antioxidant defense, measured in placental tissue homogenates. Activity was compared across the three anesthesia groups. Values are expressed in U/g of tissue.

At delivery, following placental removal.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Umbilical Cord Blood pH
Lasso di tempo: At delivery (umbilical cord blood sampling).

Umbilical cord blood pH measured by blood gas analysis immediately after delivery to assess neonatal acid-base status. Values were compared across the three anesthesia groups. pH is dimensionless.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Partial Pressure of Oxygen (pO₂)
Lasso di tempo: At delivery (umbilical cord blood sampling).

Partial pressure of oxygen (pO₂) measured in umbilical cord blood by blood gas analysis to assess neonatal oxygenation at birth. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Partial Pressure of Carbon Dioxide (pCO₂)
Lasso di tempo: At delivery (umbilical cord blood sampling).

Partial pressure of carbon dioxide (pCO₂) measured in umbilical cord blood by blood gas analysis to assess neonatal acid-base status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Base Excess (BE)
Lasso di tempo: At delivery (umbilical cord blood sampling).

Base excess (BE) measured in umbilical cord blood by blood gas analysis to assess neonatal metabolic acid-base status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

At delivery (umbilical cord blood sampling).
Umbilical Cord Blood Lactate Concentration
Lasso di tempo: At delivery (umbilical cord blood sampling).

Lactate concentration measured in umbilical cord blood by blood gas analysis to assess neonatal metabolic status at birth. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

At delivery (umbilical cord blood sampling).
Maternal Venous Blood pH
Lasso di tempo: Intraoperatively, during cesarean delivery.

Maternal venous blood pH measured by blood gas analysis during cesarean delivery to assess maternal acid-base status. Values were compared across the three anesthesia groups. pH is dimensionless.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Partial Pressure of Oxygen (pO₂)
Lasso di tempo: Intraoperatively, during cesarean delivery.

Partial pressure of oxygen (pO₂) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal venous oxygenation. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Partial Pressure of Carbon Dioxide (pCO₂)
Lasso di tempo: Intraoperatively, during cesarean delivery.

Partial pressure of carbon dioxide (pCO₂) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal acid-base and respiratory status. Values were compared across the three anesthesia groups. Results are expressed in mmHg.

Intraoperatively, during cesarean delivery.
Intraoperatively, during cesarean delivery.
Lasso di tempo: Intraoperatively, during cesarean delivery.

Lactate concentration measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal metabolic status. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

Intraoperatively, during cesarean delivery.
Maternal Venous Blood Base Excess (BE)
Lasso di tempo: Intraoperatively, during cesarean delivery.

Base excess (BE) measured in maternal venous blood by blood gas analysis during cesarean delivery to assess maternal metabolic acid-base status. Values were compared across the three anesthesia groups. Results are expressed in mmol/L.

Intraoperatively, during cesarean delivery.
Maternal White Blood Cell Count (WBC)
Lasso di tempo: Intraoperatively and 2 hours after delivery.

Maternal white blood cell (WBC) count measured in venous blood as part of a complete blood count to assess maternal hematological status. Values were compared across the three anesthesia groups. Results are expressed in ×10⁹/L.

Intraoperatively and 2 hours after delivery.
Maternal C-Reactive Protein (CRP) Concentration
Lasso di tempo: Intraoperatively and 2 hours after delivery.

Maternal C-reactive protein (CRP) concentration measured in venous blood to assess maternal inflammatory status. Values were compared across the three anesthesia groups. Results are expressed in mg/L.

Intraoperatively and 2 hours after delivery.
Intraoperatively and 2 hours after delivery.
Lasso di tempo: 48-72 hours after birth.

Neonatal white blood cell (WBC) count measured in venous blood as part of a complete blood count to assess neonatal hematological status. Values were compared across the three maternal anesthesia groups. Results are expressed in ×10⁹/L.

48-72 hours after birth.
Neonatal C-Reactive Protein (CRP) Concentration
Lasso di tempo: 48-72 hours after birth.

Neonatal C-reactive protein (CRP) concentration measured in venous blood to assess neonatal inflammatory status. Values were compared across the three maternal anesthesia groups. Results are expressed in mg/L.

48-72 hours after birth.
Maternal Mean Arterial Pressure (MAP)
Lasso di tempo: Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation, until delivery.

Maternal mean arterial pressure (MAP) was calculated from noninvasively measured systolic and diastolic arterial blood pressure values. Measurements were obtained before anesthesia and at 2-minute intervals after anesthesia initiation. MAP values were compared across the three anesthesia groups and expressed in mmHg.

Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation, until delivery.
Maternal Heart Rate (HR)
Lasso di tempo: Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation.

Maternal heart rate (HR) measured by standard intraoperative monitoring before anesthesia and at 2-minute intervals after anesthesia initiation. Measurements were compared across the three anesthesia groups. Results are expressed in beats per minute (bpm).

Before anesthesia (minute 0) and at 2, 4, 6, 8, and 10 minutes after anesthesia initiation.
Patient-Reported Anesthesia-Related Adverse Effects
Lasso di tempo: On the first postoperative day (24 hours after anesthesia).

Anesthesia-related adverse effects were assessed using the Bauer questionnaire on the first postoperative day. Ten symptoms were evaluated: postoperative pain, drowsiness, thirst, hoarseness, sore throat, nausea and vomiting, feeling cold, difficulty concentrating, pain at the anesthetic administration site, and shivering. The outcome was expressed as the number and percentage of patients reporting each adverse effect, separately for each anesthesia group.

On the first postoperative day (24 hours after anesthesia).
Intraoperative Awareness During General Anesthesia
Lasso di tempo: On the first postoperative day (24 hours after anesthesia).

Intraoperative awareness was assessed in patients receiving general anesthesia using the modified Brice questionnaire. Patients were asked about their last memory before anesthesia, first memory after awakening, any recollection of events during surgery, and dreams during anesthesia. The occurrence of reported intraoperative awareness was compared between the propofol TCI and thiopental-sevoflurane groups. The outcome was expressed as the number and percentage of patients reporting intraoperative awareness.

On the first postoperative day (24 hours after anesthesia).
Neonatal Apgar Score at 1 Minute
Lasso di tempo: 1 minute after birth.

Neonatal condition was assessed using the Apgar score at 1 minute after birth. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Each component is scored from 0 to 2, resulting in a total score ranging from 0 to 10. Apgar scores were compared across the three maternal anesthesia groups. Higher Apgar scores indicate better neonatal clinical condition.

1 minute after birth.
Neonatal Apgar Score at 5 Minutes
Lasso di tempo: 5 minutes after birth.

Neonatal condition was assessed using the Apgar score at 5 minutes after birth. The score evaluates five components: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. Each component is scored from 0 to 2, resulting in a total score ranging from 0 to 10. Apgar scores were compared across the three maternal anesthesia groups. Higher Apgar scores indicate better neonatal clinical condition.

5 minutes after birth.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 novembre 2022

Completamento primario (Effettivo)

19 febbraio 2024

Completamento dello studio (Effettivo)

19 febbraio 2024

Date di iscrizione allo studio

Primo inviato

31 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

5 novembre 2026

Primo Inserito (Effettivo)

12 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be shared because data sharing was not included in the original study protocol or informed consent procedures.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi